Vorinostat-induced bone loss might be related to drug toxicity

摘要

There is growing evidence that some HDAC inhibitors, such as trichostatin A (TSA), valproic acid (VPA), and sodium butyrate (NaBu), which all belong to the "first generation" of HDACi, could stimulate os-teogenic differentiation of mesenchymal stem cells (MSCs) and exhibit anabolic effects on the skeleton [1-5]. However, McGee-Lawrence et al. demonstrated that another pan-inhibitor of class I and II HDAC proteins, Vorinostat (SAHA or Zolinza?), caused bone loss in C57BL/6J mice by inhibition of osteoblastogenic differentiation [6]. According to our own observations [7], we wish to give our opinion about this conclusion.